Mode
Text Size
Log in / Sign up

Intramuscular quadratus lumborum block improves post-cesarean analgesia compared to anterior approachDoes a different injection spot help new moms recover faster after a C-section?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider intramuscular quadratus lumborum block for cesarean delivery to reduce early opioid use and lower extremity hypoesthesia risk.

This randomized controlled trial evaluated 128 parturients undergoing cesarean delivery, randomizing them to receive either an intramuscular quadratus lumborum block (QLB4) or an anterior quadratus lumborum block (QLB3). The study assessed analgesic efficacy and safety over a 48-hour follow-up period. Secondary outcomes included butorphanol consumption, PCA utilization, pain scores, block duration, adverse events, and maternal satisfaction. The study design supports causal inference for the reported outcomes, although specific effect sizes and absolute numbers were not reported for most metrics.

Regarding efficacy, the QLB4 group demonstrated significantly lower 24/48-hour butorphanol use and fewer PCA presses between 6 and 24 hours compared to the QLB3 group (p < 0.05 for both). Pain scores measured at 6 and 12 hours were also lower in the QLB4 group (p < 0.05). Additionally, the block resolution rate was much lower in the QLB4 group at 12 to 24 hours, indicating a longer duration of action (p < 0.05). However, no significant between-group differences were observed for late-stage opioid use or late-stage pain scores.

Safety analysis revealed a lower incidence of lower extremity hypoesthesia in the QLB4 group (0%) compared to the QLB3 group (46.88%). No significant between-group differences were found for other adverse events. Serious adverse events and discontinuations were not reported. The study did not report tolerability data or specific primary outcomes. Limitations include the absence of reported effect sizes, absolute numbers, and a specified primary outcome, which restricts the precision of the clinical interpretation.

Giving birth by C-section is a major event, and managing the pain afterward is crucial for healing. This study looked at 128 women who had this surgery. They received either an anterior quadratus lumborum block or an intramuscular quadratus lumborum block. These are two different ways to inject medicine near the spine to numb pain. The goal was to see which method helped women feel better without needing too many pain pills.

Women in the intramuscular group needed less butorphanol, a type of pain medicine, during the first 24 hours. They also pressed the button for the pain pump less often and reported lower pain scores at 6 and 12 hours. Furthermore, the block lasted longer in this group. But there was a safety difference too. Fewer women in the intramuscular group experienced numbness in their legs compared to the other group.

By 48 hours, the difference in pain scores between the two groups disappeared. Neither group needed more late-stage opioids than the other. The researchers found that the intramuscular approach offered better early relief and fewer side effects like leg numbness. This makes it a strong option for doctors to consider, but it is not a magic cure. The study did not report exact numbers for how many people used the medicine, so we cannot know the exact scale of these benefits.

What this means for you:
One injection method offers better early pain relief and fewer side effects for C-section recovery.

Study Details

Study typeRct
EvidenceLevel 2
PublishedMar 2026
View Original Abstract ↓
The goal of post-cesarean analgesia includes minimizing pain and enabling early ambulation. Quadratus lumborum block has emerged as a part of multimodal analgesia for this procedure. This randomized controlled trial compared the analgesic effects of anterior quadratus lumborum block (QLB3) and intramuscular quadratus lumborum block (QLB4). A total of 128 parturients undergoing cesarean delivery (64 per group) were enrolled in this study. Parameters including butorphanol consumption, PCA utilization, pain scores, block duration, adverse events and maternal satisfaction were assessed. QLB4 was associated with significantly lower 24/48-hour butorphanol use, less PCA pressing at 6-24 h, lower 6/12-hour NRS pain scores and a much lower block resolution rate at 12-24 h than QLB3 (all p < 0.05). QLB4 had a lower incidence of lower extremity hypoesthesia (0% vs. 46.88%), shorter procedural time, and higher maternal satisfaction scores (all p < 0.05). No significant between-group differences in late-stage opioid use, pain scores or other adverse events were found. QLB4 provides more effective, longer-lasting post-cesarean analgesia with superior safety and patient satisfaction, and greater procedural efficiency, making it a valuable multimodal analgesia option for cesarean delivery.Clinical trial registration: This trial was registered on the Chinses Clinical Trial Registry on 27/08/2025 (ChiCTR2500108272).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.